WR Wealth Planners LLC Cuts Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

WR Wealth Planners LLC trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 10.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,093 shares of the medical equipment provider’s stock after selling 614 shares during the quarter. WR Wealth Planners LLC’s holdings in Hologic were worth $367,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. State Street Corp grew its stake in Hologic by 0.8% in the 3rd quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock valued at $847,944,000 after acquiring an additional 81,057 shares during the period. FMR LLC grew its stake in Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after acquiring an additional 2,174,093 shares during the period. The Manufacturers Life Insurance Company grew its stake in Hologic by 0.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock valued at $208,051,000 after acquiring an additional 18,774 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Hologic by 8.6% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock valued at $200,952,000 after acquiring an additional 195,285 shares during the period. Finally, Nordea Investment Management AB grew its stake in Hologic by 32.7% in the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after acquiring an additional 544,889 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Trading Up 0.3 %

Shares of HOLX stock opened at $63.38 on Friday. The company’s 50-day moving average price is $69.16 and its 200-day moving average price is $75.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a market cap of $14.22 billion, a price-to-earnings ratio of 19.99, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a twelve month low of $62.69 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on HOLX. Royal Bank of Canada dropped their price target on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Evercore ISI lowered their target price on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research note on Thursday, February 6th. Mizuho lowered their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Needham & Company LLC cut shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research note on Monday, February 3rd. Finally, JPMorgan Chase & Co. lifted their target price on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Ten research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $85.77.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.88% of the stock is owned by insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.